Search results
Left in limbo: When pharma halts rare disease research
Pharmaceutical Technology· 9 hours agoLentiviral vector production represents a large portion of the high costs associated with such...
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
BioPharma Dive· 2 days agoLike many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its...